Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 12, Issue 7, Pages 855-870Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.12.7.855
Keywords
cancer; drug discovery; E3 ligases; targeted therapy; ubiquitin
Categories
Ask authors/readers for more resources
Background: The ubiquitin-proteasomal degradation pathway plays a critical role in protein degradation and regulates a wide variety of cellular functions. This highly conserved post-translational modification of proteolytic processes is mainly carried out by substrate-specific E3 ligases. The deregulation of E3 ligases contributes to cancer development and their overexpression is often associated with poor prognosis. Objectives: We review the current understanding of E3 ligases, their functional role in cancer pathogenesis, current progress and development of certain ubiquitin E3 ligases as targets for therapeutic intervention. Methods: Preclinical and clinical data for E3 ligase inhibitors available in the public domain are discussed. Conclusions: With the growing understanding of their role in cancer development and progression, E3 ligases have emerged as potential anticancer targets for therapeutic intervention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available